

Massimo Primignani

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7941474/publications.pdf>

Version: 2024-02-01

61
papers

5,189
citations

159525

30
h-index

143943

57
g-index

62
all docs

62
docs citations

62
times ranked

3795
citing authors

#	ARTICLE	IF	CITATIONS
1	Clonal Megakaryocyte Dysplasia with Normal Blood Values Is a Distinct Myeloproliferative Neoplasm. <i>Acta Haematologica</i> , 2022, 145, 30-37.	0.7	7
2	Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2276-2286.e6.	2.4	42
3	Direct oral anticoagulants for portal vein thrombosis in cirrhosis: Good news from meta-analysis?. <i>Digestive and Liver Disease</i> , 2022, 54, 54-55.	0.4	2
4	Hypercoagulability in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD): Causes and Consequences. <i>Biomedicines</i> , 2022, 10, 249.	1.4	16
5	Combined approach for embolization of otherwise unmanageable gastric varices. <i>Annals of Gastroenterology</i> , 2021, 34, 510-515.	0.4	0
6	Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal β -Blocker Therapy. <i>American Journal of Gastroenterology</i> , 2021, 116, 1342-1344.	0.2	12
7	Natural history and predictors associated with the evolution of portal venous system thrombosis in liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 33, e423-e430.	0.8	8
8	High-dose pre-endoscopic intravenous proton pump inhibitors in upper gastrointestinal bleeding: Utility or futility?. <i>Digestive and Liver Disease</i> , 2021, 53, 387-388.	0.4	1
9	Pancreatitis-related splanchnic vein thrombosis: What role, what warnings for anticoagulation therapy?. <i>Journal of Digestive Diseases</i> , 2021, 22, 122-125.	0.7	2
10	Post-banding ulcer bleeding in the elective setting: Are there any risk factors?. <i>Digestive and Liver Disease</i> , 2021, 53, 658-660.	0.4	0
11	Performance of the model for end-stage liver disease score for mortality prediction and the potential role of etiology. <i>Journal of Hepatology</i> , 2021, 75, 1355-1366.	1.8	15
12	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	1.8	28
13	Implementing pre-procedural thrombopoietin receptor agonists in cirrhotic patients with severe thrombocytopenia: Indiscriminate, selective or unneeded?. <i>Digestive and Liver Disease</i> , 2021, 53, 1394-1395.	0.4	3
14	Evolution of Nonmalignant Portal Vein Thrombosis in Liver Cirrhosis: A Pictorial Review. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00409.	1.3	8
15	Association of portal venous system thrombosis with endoscopic variceal treatment: a systematic review and meta-analysis. <i>European Journal of Gastroenterology and Hepatology</i> , 2021, 32, 125-131.	0.8	6
16	Blood Bacterial DNA Load and Profiling Differ in Colorectal Cancer Patients Compared to Tumor-Free Controls. <i>Cancers</i> , 2021, 13, 6363.	1.7	12
17	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , 2020, 71, 658-669.	3.6	95
18	Etiology of non-cirrhotic portal vein thrombosis in children: Few or many causes?. <i>Digestive and Liver Disease</i> , 2020, 52, 118-120.	0.4	0

#	ARTICLE	IF	CITATIONS
19	Plasma miRNA-based signatures in CRC screening programs. <i>International Journal of Cancer</i> , 2020, 146, 1164-1173.	2.3	35
20	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020, 95, 156-166.	2.0	53
21	Letter to the Editor: Thromboelastography-Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. <i>Hepatology</i> , 2020, 72, 1158-1159.	3.6	2
22	Nonselective β -Blockers May Progress the Thrombosis of Portal Venous System in Cirrhotic Patients: A Retrospective Observational Study. <i>Advances in Therapy</i> , 2020, 37, 1452-1463.	1.3	12
23	ABO, von Willebrand factor/factor VIII and portal vein thrombosis in decompensated cirrhosis: Too late to unmask the culprit?. <i>Liver International</i> , 2020, 40, 1788-1789.	1.9	3
24	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	1.8	112
25	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	3.6	144
26	Incidence and mortality of renal dysfunction in cirrhotic patients with acute gastrointestinal bleeding: a systematic review and meta-analysis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 1181-1188.	1.4	13
27	Assessing spleen stiffness by point shear-wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension?. <i>GastroHep</i> , 2019, 1, 205-213.	0.3	3
28	Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2019, 51, 1135-1140.	0.4	18
29	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 52-60.	1.0	8
30	Endoscopy in acute variceal bleeding: Not always the sooner, the better?. <i>Digestive and Liver Disease</i> , 2019, 51, 999-1000.	0.4	1
31	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 798-799.	2.4	0
32	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1146-1152.e4.	2.4	77
33	Changing Concepts of Cirrhotic Coagulopathy. <i>American Journal of Gastroenterology</i> , 2017, 112, 274-281.	0.2	149
34	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , 2017, 37, 694-699.	1.9	178
35	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. <i>Digestive and Liver Disease</i> , 2016, 48, 1208-1213.	0.4	20
36	Resistance to thrombomodulin is associated with <i>de novo</i> portal vein thrombosis and low survival in patients with cirrhosis. <i>Liver International</i> , 2016, 36, 1322-1330.	1.9	51

#	ARTICLE	IF	CITATIONS
37	Determinants of esophageal varices bleeding in patients with advanced hepatocellular carcinoma treated with sorafenib. <i>United European Gastroenterology Journal</i> , 2016, 4, 363-370.	1.6	16
38	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016, 48, 455-467.	0.4	57
39	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , 2015, 63, 1118-1125.	1.8	74
40	Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. <i>Leukemia Research</i> , 2015, 39, 525-529.	0.4	17
41	Diagnosis of thrombophilia/prothrombotic conditions in patients with liver disease. <i>Clinical Liver Disease</i> , 2014, 3, 126-128.	1.0	4
42	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014, 61, 148-154.	1.8	149
43	Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. <i>Digestive and Liver Disease</i> , 2014, 46, 152-156.	0.4	38
44	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. <i>Journal of Hepatology</i> , 2013, 59, 265-270.	1.8	146
45	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. <i>Liver International</i> , 2013, 33, 362-367.	1.9	107
46	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , 2012, 7, 139-144.	1.0	96
47	Acute portal vein thrombosis unrelated to cirrhosis: A prospective multicenter follow-up study. <i>Hepatology</i> , 2010, 51, 210-218.	3.6	458
48	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , 2010, 52, 249-255.	3.6	123
49	Portal vein thrombosis, revisited. <i>Digestive and Liver Disease</i> , 2010, 42, 163-170.	0.4	119
50	High levels of factor VIII and risk of extra-hepatic portal vein obstruction. <i>Journal of Hepatology</i> , 2009, 50, 916-922.	1.8	69
51	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , 2009, 51, 288-295.	1.8	26
52	An Imbalance of Pro- vs Anti-Coagulation Factors in Plasma From Patients With Cirrhosis. <i>Gastroenterology</i> , 2009, 137, 2105-2111.	0.6	472
53	Etiology, Management, and Outcome of the Budd-Chiari Syndrome. <i>Annals of Internal Medicine</i> , 2009, 151, 167.	2.0	422
54	The Role of Thrombophilia in Splanchnic Vein Thrombosis. <i>Seminars in Liver Disease</i> , 2008, 28, 293-301.	1.8	47

#	ARTICLE	IF	CITATIONS
55	MPL and JAK2 exon 12 mutations in patients with the Budd-Chiari syndrome or extrahepatic portal vein obstruction. <i>Blood</i> , 2008, 111, 4418-4418.	0.6	30
56	Reply:. <i>Hepatology</i> , 2007, 45, 832-833.	3.6	1
57	The international normalized ratio calibrated for cirrhosis (INRliver) normalizes prothrombin time results for model for end-stage liver disease calculation. <i>Hepatology</i> , 2007, 46, 520-527.	3.6	179
58	Thrombin generation in patients with cirrhosis: The role of platelets. <i>Hepatology</i> , 2006, 44, 440-445.	3.6	347
59	Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. <i>Hepatology</i> , 2006, 44, 1528-1534.	3.6	249
60	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. <i>Hepatology</i> , 2005, 41, 553-558.	3.6	617
61	Risk factors for thrombophilia in extrahepatic portal vein obstruction. <i>Hepatology</i> , 2005, 41, 603-608.	3.6	190